BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Minami T, Takeda M, Sata M, Kato H, Yano K, Sakai T, Tsujita R, Kawasaki K, Ito A. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. Eur J Pharmacol 2020;880:173196. [PMID: 32416186 DOI: 10.1016/j.ejphar.2020.173196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Sekiguchi F, Kawabata A. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 2020;22:E367. [PMID: 33396481 DOI: 10.3390/ijms22010367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.01.006] [Reference Citation Analysis]
3 Kawashiri T, Mine K, Kobayashi D, Inoue M, Ushio S, Uchida M, Egashira N, Shimazoe T. Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence. Int J Mol Sci 2021;22:1393. [PMID: 33573316 DOI: 10.3390/ijms22031393] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Taniguchi K, Ohbe H, Yamakawa K, Matsui H, Fushimi K, Yasunaga H. Recombinant Thrombomodulin in Disseminated Intravascular Coagulation Associated with Stage IV Solid Tumors: A Nationwide Observational Study in Japan. Thromb Haemost 2021;121:36-45. [PMID: 32906154 DOI: 10.1055/s-0040-1715840] [Reference Citation Analysis]
5 Miyamoto T, Hiramoto S, Kanto A, Tsubota M, Fujitani M, Fukuyama H, Hatanaka S, Sekiguchi F, Koizumi Y, Kawabata A. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study. J Pharmacol Sci 2021;146:49-57. [PMID: 33858655 DOI: 10.1016/j.jphs.2021.03.001] [Reference Citation Analysis]